- Trials with a EudraCT protocol (71)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (14)
71 result(s) found for: Childhood cancer.
Displaying page 1 of 4.
EudraCT Number: 2015-004251-47 | Sponsor Protocol Number: SAFE-PEDRUG-02 | Start Date*: Information not available in EudraCT |
Sponsor Name:UZ Brussel | ||
Full Title: Validation of central venous (Port A Cath®) blood draws for ciprofloxacin pharmacokinetic research in patients under treatment for childhood cancer. | ||
Medical condition: Childhood cancer | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004541-33 | Sponsor Protocol Number: immvzmpr1 | Start Date*: Information not available in EudraCT |
Sponsor Name:Västra Götalandsregionen | ||
Full Title: A clinical study to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in childhood cancer. | ||
Medical condition: This study will be conducted as a longitudinal study. Former studies have shown that immunity is affected after treatment against childhood cancer. We want to investigate humoral and cell-mediated ... | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2006-000492-16 | Sponsor Protocol Number: CCR2739 | Start Date*: 2006-07-20 | |||||||||||
Sponsor Name:Royal Marsden Foundation Hospital | |||||||||||||
Full Title: A Phase II, Single-Centre, Randomised, Controlled, Open-Label Clinical Trial to Compare the Efficacy and Safety of Three Therapeutic Interventions on the Treatment of Hypothalamic Obesity due to Ch... | |||||||||||||
Medical condition: Hypothalamic Obesity due to Childhood Cancer with Cranial Insults | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003303-30 | Sponsor Protocol Number: 2014-003303-30 | Start Date*: 2015-05-22 | |||||||||||
Sponsor Name:Dutch Childhood Oncology Group | |||||||||||||
Full Title: TropicALL study; Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a randomized controlled trial | |||||||||||||
Medical condition: Acute lymphoblastic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015163-14 | Sponsor Protocol Number: 73191198 | Start Date*: 2010-01-08 | ||||||||||||||||
Sponsor Name:Department of Pediatrics Aarhus University Hospital Skejby | ||||||||||||||||||
Full Title: Reduction of hypertrophic scars and keloid by use of corticosteroid cream after removal of a tunneled central venous catheter in childhood cancer survivors | ||||||||||||||||||
Medical condition: Development of hypertrophic and keloid scars after removal of tunneled central venous catheters in childhood cancer survivors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002845-36 | Sponsor Protocol Number: PK200609 | Start Date*: 2006-11-14 |
Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust | ||
Full Title: Pharmacokinetics and pharmacogenetics of anticancer drugs in infants and young children | ||
Medical condition: Any childhood cancer. | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-000186-40 | Sponsor Protocol Number: B1931036 | Start Date*: 2022-10-07 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PROSPECTIVE, RANDOMIZED, OPEN-LABEL PHASE 2 STUDY TO EVALUATE THE SUPERIORITY OF INOTUZUMAB OZOGAMICIN MONOTHERAPY VERSUS ALLR3 FOR INDUCTION TREATMENT OF CHILDHOOD HIGH RISK FIRST RELAPSE B-CELL... | |||||||||||||
Medical condition: Acute Lymphoblastic Leukemia (ALL) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) SK (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Trial now transitioned) CZ (Ongoing) NL (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002675-19 | Sponsor Protocol Number: TMZ-CSF-001 | Start Date*: 2015-10-06 |
Sponsor Name:Medical University of Vienna, Department of Pediatrics | ||
Full Title: Pharmacokinetics of temozolomide in cerebrospinal fluid in children with malignant brain tumors | ||
Medical condition: Recurrent malignant childhood central nervous system tumors | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-006239-44 | Sponsor Protocol Number: NL37603.042.11 | Start Date*: 2012-10-02 |
Sponsor Name:Dutch Childhood Oncology Group | ||
Full Title: An international collaborative study to discontinue Imatinib/Glivec® in pediatric CML patients with sustained complete molecular response (STOPIMAPED) | ||
Medical condition: Chronic Myeloid Leukemia pediatric patients treated with Imatinib having achieved and maintained complete molecular remission for at least 2 years. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-014037-25 | Sponsor Protocol Number: ITCC021 | Start Date*: 2010-01-11 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: Bortezomib (Velcade®): a feasibility and phase II study in childhood relapsed acute lymphoblastic leukemia | |||||||||||||
Medical condition: acute lymphoblastic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) IT (Completed) BE (Completed) DK (Prematurely Ended) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000533-13 | Sponsor Protocol Number: Randomet2017 | Start Date*: 2019-12-05 |
Sponsor Name:Gesellschaft für Pädiatrische Onkologie und Hämatologie gGmbH | ||
Full Title: Randomized multi-centre open-label non-inferiority phase 3 clinical trial for patients with a stage IV childhood renal tumour comparing upfront Vincristine, Actinomycin-D and Doxorubicin (VAD, stan... | ||
Medical condition: Stage IV childhood renal tumours | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) AT (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) CZ (Ongoing) DK (Trial now transitioned) NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000793-30 | Sponsor Protocol Number: IntReALL-SR-2010 | Start Date*: 2013-10-25 | |||||||||||
Sponsor Name:Charité - University Hospital of Berlin | |||||||||||||
Full Title: International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 | |||||||||||||
Medical condition: Acute lymphoblastic leukemia (ALL) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) PT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) AT (Completed) IE (Completed) FI (Completed) DK (Completed) CZ (Completed) IT (Completed) NL (Completed) FR (Completed) PL (Completed) ES (Prematurely Ended) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001236-21 | Sponsor Protocol Number: 2008-003235-20 | Start Date*: 2013-06-11 | |||||||||||
Sponsor Name:Kjeld Schmiegelow | |||||||||||||
Full Title: Plasma kinetics for tablet and liquid formulations of 6-mercaptopurine in childhood acute lympholastic leukemia | |||||||||||||
Medical condition: Childhood acute lymphoblastic leukemia. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004128-41 | Sponsor Protocol Number: WN42086 | Start Date*: 2021-08-24 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICACY OF OCRELIZUMAB IN COMPARISON WITH FINGOLIMOD IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTI... | |||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) BG (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001438-25 | Sponsor Protocol Number: VWM1 | Start Date*: 2020-04-21 |
Sponsor Name:VU University Medical Center | ||
Full Title: A Study to Explore the Safety, Tolerability, Pharmacokinetic Profile, and Potential Efficacy of Guanabenz in Patients With Early Childhood Onset Vanishing White Matter (VWM) | ||
Medical condition: Vanishing white matter | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000015-24 | Sponsor Protocol Number: 07MI05 | Start Date*: 2015-04-10 |
Sponsor Name:Great Ormond Street Hospital | ||
Full Title: 90-Yttrium-labelled anti-CD66 monoclonal antibody as part of a reduced intensity conditioning regimen prior to allogeneic haematopoietic stem cell transplantation: an open label, dose escalating ph... | ||
Medical condition: High risk relapsed or refractory leukaemia in childhood | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000466-33 | Sponsor Protocol Number: PT/11/2015 | Start Date*: 2016-03-22 | |||||||||||
Sponsor Name:Department of Pediatric oncology, Aarhus University hospital | |||||||||||||
Full Title: Pharmacokinetics and pharmacodynamics of Piperacillin-Tazobactam (PT) in pediatric oncology patients with fever and neutropenia. | |||||||||||||
Medical condition: Pediatric oncology patients with fever and neutropenia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004266-15 | Sponsor Protocol Number: ARYHM-1 | Start Date*: 2012-01-18 | |||||||||||
Sponsor Name:RMC, Skåne University Hospital | |||||||||||||
Full Title: Androgen replacement in young hypogonadal men: a 2 year randomized, double-blind placebo controlled study | |||||||||||||
Medical condition: Target population: Male hypogonadism (testosterone deficiency) As end points Bone mineralisation Body composition Markers of insulin sensitivity and cardiovascular disease Lipid profile H... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: SE (Ongoing) NO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000810-12 | Sponsor Protocol Number: IntReALL-HR-2010 | Start Date*: Information not available in EudraCT |
Sponsor Name:Charité - Universitätsmedizin Berlin | ||
Full Title: IntReALL HR 2010 International Study for Treatment of High Risk Childhood Relapsed ALL 2010 | ||
Medical condition: Acute lymphoblastic leukemia (ALL) | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Ongoing) DE (Trial now transitioned) DK (Prematurely Ended) PT (Trial now transitioned) AT (Trial now transitioned) NO (Ongoing) FI (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022946-25 | Sponsor Protocol Number: AALL0622 | Start Date*: 2011-12-19 | ||||||||||||||||
Sponsor Name:Children's Oncology Group | ||||||||||||||||||
Full Title: Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib: IND# 73969, NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) | ||||||||||||||||||
Medical condition: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
